About the Company
inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NSPR News
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.2. InspireMD, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
InspireMD, Inc. NSPR recently announced its receipt of CE Mark recertification under the European Union’s (EU) new Medical ...
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and ...
InspireMD (NSPR) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
VIVE Viveve Medical, Inc.
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function ...
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and ...
InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript
Greetings. Welcome to InspireMD Fourth Quarter and Full Year 2023 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to ...
InspireMD, Inc.: InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and ...
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD ...
Loading the latest forecasts...